IGM Biosciences (IGMS)
(Real Time Quote from BATS)
$6.44 USD
-1.52 (-19.10%)
Updated Apr 25, 2024 11:31 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IGMS 6.44 -1.52(-19.10%)
Will IGMS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGMS
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade
Other News for IGMS
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)
IGM Biosciences weakness creates 'interesting opportunity,' says Stifel
What 5 Analyst Ratings Have To Say About IGM Biosciences
IGM Biosciences Announces Refocusing of Sanofi Collaboration